Publishing Beyond the Printed Page - - BioPharm International

ADVERTISEMENT

Publishing Beyond the Printed Page


BioPharm International
Volume 27, Issue 4

With the growth of digital publishing options, the traditional magazine article has taken on a new form. For editors, this is good news, providing opportunity to expand coverage in terms of length, scope, and format. In the past few months,

BioPharm International has published two eBooks, initiated video and audio content, and mapped plans for an upgraded website to build upon the traditional print magazine. While the traditional “article” has evolved to diverse “media,” the core value of the content remains the same. The editors seek quality, objective contributions from bioprocessing experts. The following is a summary of our editorial guidelines.

BioPharm International covers the science and business of biopharmaceutical development and manufacturing. The content includes peer-reviewed manuscripts and practical, technical articles and columns. The editors believe that technical decisions are also business decisions; readers need information and tools to make appropriate technical and business choices.

BioPharm International readers are PhD-level researchers, scientists, and engineers involved in product and process development, manufacturing, quality control/quality assurance, analytical technologies, regulatory affairs, and plant and project engineering and design. Other readers are corporate managers, particularly in startup or virtual biopharmaceutical companies. Readers are involved in the development of a broad spectrum of biopharmaceutical products, including therapeutic peptides, proteins, nucleic acids, and cells for cell therapies and regenerative medicine, as well as both therapeutic and prophylactic vaccines.

BioPharm International publishes peer-reviewed papers, non peer-reviewed technical papers, and business-focused articles. The submission guidelines differ for each article type. If you are unsure about the most appropriate format, contact the editors.

Articles cover technical and regulatory subjects such as upstream processing functions of protein expression, fermentation and cell culture; downstream processing including separation and purification; process development; drug formulation and delivery; validation; GMP compliance and quality control; analytical technologies; scale-up strategies; and facilities design. The magazine also covers business topics such as supply-chain management, sourcing and outsourcing, project management, partnerships, and intellectual property management.

BioPharm International seeks contributions from all participants in the biopharmaceutical development community. Manuscripts are reviewed with the understanding that they have not been published previously, are not ghostwritten, and are not under consideration for publication elsewhere, including on the Internet.

Peer-reviewed submissions do not have specific deadlines. Peer-reviewed articles usually take approximately two months for review, revision, and acceptance by the editors. Once accepted, an article is published within four to eight months. Articles for supplements and non peer-reviewed articles are typically assigned three to five months before the supplement is published. If your topic is accepted, an editor will assign you an official deadline, approximately six weeks before the publication date.

First, visit www.biopharminternational.com/Contribute and review the author’s guidelines and editorial calendar. These instructions provide details about formats, style, and submission procedures. Then, send me a message or give me a call. I would be happy to discuss your ideas for contributions.

Rita Peters
Rita Peters

About the Author
Rita Peters is the editorial director of BioPharm International.

 

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here